Bob Smith | Senior Vice President, Global Gene Therapy Business

Bob Smith, Senior Vice President, Global Gene Therapy Business, Pfizer

Bob is an accomplished biopharmaceutical executive with over thirty years’ experience in a variety of alliance management, business development, commercial, corporate, and research and development roles. Bob is responsible for leading Pfizer’s Global Gene Therapy Business including the strategic and operational development and implementation of Pfizer’s enterprise-wide efforts to be an industry leader in gene therapy.

Prior his current role, Bob was responsible for leading and managing the Worldwide Business Development activities for Pfizer’s Worldwide Research and Development organization as well as Pfizer’s Strategic Transactions team. During his tenure at Pfizer, Bob also had responsibility for leading and managing the business development teams for Pfizer’s Animal Health, Capsugel, Consumer Healthcare and Nutrition Business Units and the Alliance Management function supporting Pfizer’s Biopharmaceutical Business Units and the Worldwide Research and Development organization.

Bob joined Pfizer from Wyeth in October 2009, following Pfizer’s acquisition of Wyeth, where he was responsible for leading and managing Wyeth’s Global Mergers and Acquisitions group. He was also responsible for the global mergers and acquisitions activities for Wyeth’s Consumer Healthcare division and its Fort Dodge Animal Health division. Prior to this role, Bob was Senior Vice President, Global Licensing, Wyeth Pharmaceuticals, where he completed a wide variety of transactions in support of Wyeth’s commercial and research and development divisions.

Bob serves a member of the Board of Directors of AM Pharma B.V. (Observer), Bamboo Therapeutics Inc. (acquired by Pfizer in August 2016), Ignite Immunotherapeutics Inc., Iterum Therapeutics Limited (Observer), Life Sciences PA – the Pennsylvania Biotechnology Association and the Alliance for Regenerative Medicine.

Bob obtained a B.S. in Neuroscience from the University of Rochester and an M.B.A. in Finance and Corporate Accounting from the William E. Simon Graduate School of Business Administration at the University of Rochester, Rochester, New York.


Conference Day 1: Thursday 16th May 2019 @ 09:30

(ex vivo) Gene edited therapeutics and (in vivo) gene therapy: how can gene technology be used now and, in the future, to treat and cure diseases in the clinic

  • How does gene editing apply to the clinic?
  • How is it currently being applied?
  • How can we improve delivery of AAVs into the cell?
  • Improving the volume of viral particles: what stages do we need to cover to get to a commercial scale?
  • Moving into larger diseases from rare diseases, what challenges need to be overcome?
  • Risk/benefit acceptance of the general population and the medical system.
  • What is the real risk of CRISPR causing cancer as published by Novartis and KI?
  • How do we want to use it in the future and what challenges need to be overcome to do so? (immunogenicity, off target effects and efficacy, being vigilant with safety profiles, potency and manufacturing, moving towards direct, in vivo [bluebird bio live delivery usingnanoparticles], viral and non-viral)
  • How do you move towards that goal in a way that engages stakeholders? Applications

Conference Day 1: Thursday 16th May 2019 @ 14:15


last published: 25/Mar/19 17:15 GMT

back to speakers

There are two parts to the World Advanced Therapies & Regenerative Medicine Congress: a conference and an exhibition featuring solutions for pharma and biotech.

There is a registration fee to attend the conferences. To visit the exhibition is free.


Erica Baeta 
+44 (0)207 092 1152


Jessica Robinson 
t/ +44 (0)207 092 1150


Issa Mauthoor 
+44 (0)207 092 1257